Market closed

Pacific Biosciences/$PACB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Ticker

$PACB
Sector
Health Care
Trading on
NASDAQ

Industry

Life Sciences Tools & Services
Headquarters
Menlo Park, United States

Employees

796
Website
www.pacb.com

PACB Metrics

BasicAdvanced
$550M
-
-$1.46
2.01
-

$550M

2.01

$7.50

$1.16

8.7M

9.738

8.343

200.846

203.202

-19.98%

-11.37%

-64.80%

3.141

1.21

-1.56

-2.27

2.14%

14.99%

12.49%

97.66%

What the Analysts think about PACB

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.

PACB Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PACB Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

PACB News

AllArticlesVideos
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

GlobeNewsWire·16 hours ago
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

GlobeNewsWire·17 hours ago
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PACB

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pacific Biosciences stock?

Pacific Biosciences (PACB) has a market cap of $550M as of January 15, 2025.

What is the P/E ratio for Pacific Biosciences stock?

The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of January 15, 2025.

Does Pacific Biosciences stock pay dividends?

No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Pacific Biosciences dividend payment date?

Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.

What is the beta indicator for Pacific Biosciences?

Pacific Biosciences (PACB) has a beta rating of 2.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.